Valuation: Aquestive Therapeutics, Inc.

Market Cap 53Cr 46Cr 43Cr 40Cr 74Cr 5.09TCr 76Cr 510.36Cr 199.24Cr 2.55TCr 200.26Cr 195.93Cr 8.5TCr P/E 2026 *
-8.08x
P/E 2027 * -8.56x
Enterprise Value 46Cr 39Cr 37Cr 34Cr 63Cr 4.35TCr 65Cr 435.73Cr 170.11Cr 2.18TCr 170.98Cr 167.28Cr 7.26TCr EV / Sales 2026 *
9.11x
EV / Sales 2027 * 7.75x
Free-Float
96.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week+8.42%
Current month+15.02%
1 month+4.68%
3 months+2.91%
6 months+16.44%
Current year-34.21%
1 week 4.14
Extreme 4.14
4.69
1 month 3.56
Extreme 3.56
4.69
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Sell

Chief Executive Officer

-20,369 0.0162%
09/03/26 Free

General Counsel

2,00,311 0.1642%
09/03/26 Other

Chief Operating Officer

1,68,291 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%+8.42%+5.99%+119.07% 53Cr
-0.92%+1.43%+83.05%+128.86% 1,07800Cr
+0.47%+1.98%+50.26%+50.75% 63TCr
+0.83%+2.85%+24.49%+64.82% 44TCr
-1.50%-2.91%+42.58%+34.64% 36TCr
-1.28%-3.06%+23.89%+34.32% 29TCr
-1.56%-3.23%-0.64%+3.58% 25TCr
+0.40%+3.21%+44.42%+59.17% 23TCr
+0.60%-1.59%-7.47%-51.52% 20TCr
+1.67%+5.56%+14.98%+72.68% 17TCr
Average -0.38%+2.13%+28.15%+51.64% 36.44TCr
Weighted average by Cap. -0.40%+1.30%+45.30%+65.36%

Financials

2026 *2027 *
Net sales 5Cr 4.33Cr 4.06Cr 3.7Cr 6.97Cr 477.2Cr 7.08Cr 48Cr 19Cr 238.88Cr 19Cr 18Cr 796.86Cr 6.89Cr 5.97Cr 5.6Cr 5.1Cr 9.6Cr 657.31Cr 9.76Cr 66Cr 26Cr 329.04Cr 26Cr 25Cr 1.1TCr
Net income -6.55Cr -5.67Cr -5.32Cr -4.85Cr -9.13Cr -624.81Cr -9.27Cr -63Cr -24Cr -312.77Cr -25Cr -24Cr -1.04TCr -6.2Cr -5.38Cr -5.04Cr -4.6Cr -8.65Cr -592.02Cr -8.79Cr -59Cr -23Cr -296.35Cr -23Cr -23Cr -988.6Cr
Net Debt -7.8Cr -6.76Cr -6.34Cr -5.78Cr -11Cr -744.43Cr -11Cr -75Cr -29Cr -372.64Cr -29Cr -29Cr -1.24TCr -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
13/26/13 $4.250 +0.47% 37,45,394
12/26/12 $4.230 -4.08% 91,16,267
11/26/11 $4.410 +2.80% 64,95,034
10/26/10 $4.290 +8.88% 72,95,514
07/26/07 $3.940 +0.51% 18,60,430
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.250USD
Average target price
9.222USD
Spread / Average Target
+116.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock